A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.
Elizabeth Marie GavioliNerli GuardadoFarah HaniffNouran DeiabEtty ViderPublished in: Journal of clinical pharmacy and therapeutics (2020)
Cystic fibrosis transmembrane conductance regulator agents are generally well tolerated with low discontinuation rates when compared to placebo. Elevations in liver enzymes and drug-drug interactions are the most notable safety concerns. Additionally, lumacaftor/ivacaftor has shown more respiratory-related adverse events and drug-drug interactions compared to elexacaftor/tezacaftor/ivacaftor and tezacaftor/ivacaftor. Postmarketing studies are needed to determine long-term safety concerns.